D8/D9 Activity Annual Review Webinar
Register to join the D8/D9 Activity Annual Review Webinar by John Somers, Senior Manager EHS on Monday, December 29th at 5:30 pm – 6:30 pm EST. This will be an online event. You can register to attend with the link below: https://events.teams.microsoft.com/event/ecd66a06-e39a-42eb-859e-5bacfad9cbd2@eecbd9c7-c2bb-4168-95d6-ee6184270874
The Security of Onshore Manufacturing
Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.
Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.
Diversifying the Supply of Raw Materials
Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.
Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.
Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Noramco announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.
Noramco Celebrates Diversity and International Women’s Day
Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC.
Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient
Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC.
Meet us at DCAT Week
Meet us at DCAT Week, the premier business development event for companies engaged in pharmaceutical development and manufacturing.